Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 10/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | MASP2 | O00187 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765806 | 0.95 | MAPK1 (0.36) | MAPK1F2USP2NAMPTHDAC6 | |
| SCHEMBL30765642 | 0.89 | MAPK1 (0.35) | MAPK1F2USP2POLBGAA | |
| SCHEMBL30765750 | 0.89 | MAPK1 (0.34) | MAPK1F2USP2POLBGAA | |
| SCHEMBL30765625 | 0.88 | F2 (0.36) | MAPK1F2USP2GAAHTT | |
| SCHEMBL30765543 | 0.88 | ELANE (0.39) | MAPK1F2F3 | |
| SCHEMBL30766121 | 0.88 | MAPK1 (0.34) | MAPK1F2HDAC6 | |
| SCHEMBL30765871 | 0.87 | F2 (0.36) | MAPK1F2USP2GAAHTT | |
| SCHEMBL31558497 | 0.87 | F2 (0.35) | MAPK1F2USP2GAAHTT | |
| SCHEMBL30765885 | 0.87 | MAPK1 (0.34) | MAPK1F2USP2POLBGAA | |
| SCHEMBL30765516 | 0.87 | NTRK1 (0.35) | MAPK1F2USP2GAAF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |